AI Header Page

Data Solutions for Artificial Intelligence in Drug Discovery and Diagnostics

    Supporting Increased Success Rates for Your AI

    The use of machine-learning-based techniques in drug discovery requires copious amounts of biomedical data. At BioIVT, we have H&E images and associated data from over 30 years of biospecimen and clinical data procurement that are ready to be incorporated into your target discovery and drug development workflows. You can use our specimen database to discover patterns and relationships relevant to both disease etiology and pathology.


    Partner with Us for a Custom Solution

    Clinical Data from Over 1 Million Biospecimens

    BioIVT’s ASTERAND® Human Tissue Repository has serviced the drug discovery and diagnostic industry since 1996 with high quality, well-characterized human tissue biospecimens and related clinical data. We have procured over 1 million tissues through an unparalleled worldwide network of over 425 active donor institutions, all using standard protocols and adhering to the highest standards of sample integrity. At any one point in time, our biobank contains hundreds of thousands of specimens from a broad range of therapeutic areas and from many ethnicities. Our renowned quality assurance procedures provide stringent controls on specimen collection, characterization and the corresponding clinical data.

    BioIVT collects every sample under IRB-approved protocols, ensuring that strict ethical guidelines are followed to protect patient confidentiality and safety. The samples are identifiable only by barcodes to ensure an unbiased assessment and patient confidentiality. Each sample has either the patient's consent or IRB-approved waiver of consent for use in a wide range of research, including the development of commercial products or services. Blinded IRB and informed consent documentation are provided prior to purchase to ensure that all specimens and regulatory documents meet client requirements.

    • Ongoing procurement of human specimens, with over 200,000 specimens procured to BioIVT’s ASTERAND® Human Tissue standards
    • Board-certified pathology review of every block
    • Comprehensive clinical data independently reviewed by BioIVT specialists and verified by board-certified pathologists
    • Full regulatory approval of all specimens

    Board Certification Pathology-Confirmed Diagnosis

    We understand that a tissue specimen is only as good as the data associated with it. That’s why the biospecimens and associated data in BioIVT’s ASTERAND Human Tissue Repository undergo a thorough review by board-certified pathologists and a clinical data team. By confirming the original diagnosis for normal, diseased and tumor tissues, our pathologists ensure that the tissue blocks are representative of the donor’s diagnosis. This is important because while a patient may have a specific diagnosis, each block prepared from resected tissue may not represent that diagnosis. Our process, in place over the course of our history, ensures that data and images correlate and support your machine-learning.

    Hear our head pathologist, Dr. Alex Green, discuss how he uses his clinical background to ensure a consistent experience for every BioIVT client

    Key features of our process:

    • Pathological data is classified using ICD codes as appropriate for anatomic site, morphology and behavior with WHO Oncology Classifications for tumor indications
    • Data complies with WHO Oncology Classifications for tumor indications
    • Clinical data is pathologist-confirmed for completeness and consistency
    • All tissue specimens are provided with up to 200 clinical data points and histological information per case, including:
      • % tumor
      • % normal
      • % necrosis
      • % other
    • Quality analysis includes RIN for fresh-frozen specimens

    Full-Slide Images Integrate into Machine Learning–Based Image Analysis

    In 2016, BioIVT added Aperio Digital Pathology Slide Scanners into our tissue pathology review process, allowing clients to review full-slide H&E images with exceptional quality, speed and reliability. We have also scanned many of our historical cases, as the H&E slide and data associated with each case has been maintained for all specimens procured.

    Use our digital portal to search our live inventory, or use a curated search output from our trained team of Search Engineers who will personally select the best specimens to fit your needs. In either case, you’ll have a clear picture of what you’re buying before you make your purchase.

    Enhanced Data to Further Your Understanding

    Outcomes and mutation analysis is an important research and diagnostic tool for studying cancer and other diseases.

    Outcome data provides elemental indicators for both drug discovery and diagnostic researchers. BioIVT’s standard outcome-collected data aligns with the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program, and our comprehensive, independently reviewed set of over 200 data points includes:

    • Clinical donor diagnosis and status
    • Co-morbidities and treatments (current and past)
    • Medications, AJCC/UICC stage and group independently reviewed by BioIVT
    • Cause of death (if available)

    BioIVT’s long-standing relationships with our partner sites allow for continued procurement of outcome data from patients who have consented and donated tissues to our ASTERAND Human Tissue Repository.

    Mutation analysis is now being used as a diagnostic tool for many diseases, including cancer. Diagnostic assays for specific biomarkers for patient stratification are in ever-expanding development. BioIVT supports these efforts through standard mutation analysis for lung, melanoma and colon cancers, as well as custom mutation screenings on tissues and biofluids.

    We can also use the following methods to provide additional data:

    • qRT-PCR is effective for determining the status of various somatic mutations in human tissue samples
    • Sanger/Pyrosequencing provides single nucleotide variations within DNA or RNA, or can be used for sequencing gene sections (exons)
    • Next Generation Sequencing (NGS) is effective for determining the presence of SNV, CNV or fusions across multiple genes
    • Immunohistochemistry (IHC) provides useful information in determining protein overexpression
    We offer biomarker analysis on specific cohorts and the ability to screen as a custom project: ER/PR/HER2, EGFR, KRAS, BRAF, MSI, NGS Tumor Panels, Fusions, CNVs, HLA and more.